Fluid AI Medical, a Canadian medical technology company, shared the news that the U.S. Food and Drug Administration has given the green light for its Origin system. This inline biosensor is designed to monitor surgical drain fluid in real time at the patient’s bedside right after surgery. The Origin system can work on its own or be connected with the Stream Care AI-assisted Surgical Expert Suite, offering continuous pH data that allows clinical teams to closely watch how patients are recovering. The system connects easily to standard surgical drains and shows real-time biochemical changes directly at the bedside.
Health Technology Insights: Cairns Health Expands Luna Digital Care Nationwide
Youssef Helwa, CEO of Fluid AI Medical, called the FDA approval a big achievement for the company’s goal of using data to improve postoperative care. He explained that the device changes how traditional measurements are taken, moving from occasional checks to constant monitoring. This allows doctors to spot small changes in the patient’s biochemistry early, which can signal whether healing is going well or if issues might be arising. Helwa noted that Origin is not meant to diagnose complications in the U.S., but the continuous data helps predictive algorithms, pushing healthcare towards a more proactive rather than reactive way of managing recovery.
Health Technology Insights: Sai Life Sciences Opens Dedicated Facility for Veterinary APIs in Bidar, India
Ricky Tjandra, Director of Research and Development, said the clearance is an important step toward their goal of turning surgical fluid data into useful information. He pointed out the potential of this overlooked data source to support advanced machine learning models that can create personalized recovery plans, lower the number of hospital readmissions, and save lives by spotting problems earlier.
Guenevere O’Hara, Global Business Development Manager at Fluid AI Medical, mentioned that many important medical breakthroughs have come from making unseen processes visible through data. She suggested that by looking at intraperitoneal fluid and surgical drain fluid not as waste, but as a changing reflection of the abdominal cavity’s status, continuous monitoring could change postoperative care for the nearly 500,000 gastrointestinal surgeries done worldwide each year.
With support from government agencies, top research institutions, and healthcare providers in North America, Europe, and the Middle East, Fluid AI Medical is broadening the use of its Origin system with this FDA approval, aiming to bring smarter and more responsive recovery monitoring to hospitals around the world.
Health Technology Insights: Cardiosense Appoints Eric Meizlish as CEO to Advance AI-Enabled Cardiac Care
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
